Lung Cancers Today
Advertisement
Researchers presented an updated safety and efficacy analysis at the ESMO 2024 Congress.
The trial is evaluating perioperative pembrolizumab plus sacituzumab govitecan for certain patients with NSCLC.
Researchers shared an updated safety analysis from the trial at the IASLC 2024 World Conference on Lung Cancer.
The KEYNOTE-483 trial showed a significant improvement in OS with the addition of pembrolizumab to chemotherapy.
Dr. Li discusses important thoracic oncology data presented at the ESMO 2024 Congress, which was held in Barcelona, Spain
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Benjamin Besse, MD, PhD, shares insights from the research he presented as a late-breaking abstract at ESMO 2024.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
Dr. Halmos weighs in on HARMONi-2, TROPION-Lung 01, the SOHO-01 and Beamion LUNG-1 studies, and more.
The study evaluated multiple prophylactic strategies to mitigate infusion-related reactions with IV amivantamab.
Martin Reck, MD, PhD, shares his insights on key data in lung cancer to be presented at the ESMO Congress 2024.
Rilertinib showed significantly longer progression-free survival compared with gefitinib.
The studies were highlighted as plenary presentations during a Presidential Symposium at WCLC 2024.
Plinabulin combined with docetaxel showed improved survival in patients with wild-type EGFR NSCLC.
Eric Singhi, MD, and Bruna Pellini, MD, joined Lung Cancers Today at the conference to share their insights on key data.
Narjust Florez, MD, FASCO, discusses meeting highlights, the IASLC 50th Anniversary Celebration, research, and more.
Shirish M. Gadgeel, MD, discusses his presentation on the updated data, with a median follow-up of 31.1 months.
Osimertinib demonstrated a manageable safety profile for the treatment of stage III EGFR-mutated NSCLC.
Caicun Zhou, PhD, MD, presented results during the first Presidential Symposium at the IASLC 2024 WCLC.
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.